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Background: The current mainstream treatment for COPD is bronchodilators alone or in combi-
nation. The effects of a b2-agonist, tulobuterol, administered transdermally, have been
reported to last for 24 h. However, there are no reports on the efficacy of tulobuterol
combined with an anticholinergic. In this study, we investigated the efficacy and safety of
transdermal tulobuterol combined with inhaled tiotropium in COPD.
Methods: After a 2-week run-in period, 103 stable COPD patients aged 40 years were random-
ized into two groups: inhaled tiotropium (18 mg, Tio group) or transdermal tulobuterol (2 mg)
combined with inhaled tiotropium (18 mg, Tioþ Tulo group) for 8 weeks. Primary endpoints
were pulmonary function and severity of dyspnea. The St. George’s Respiratory Questionaire
(SGRQ) score was a secondary endpoint.
Results: In both groups, FEV1 and FVC as well as dyspnea improved significantly after 8 weeks.
In a comparison of both groups, percentage changes in IC and morning and evening peak expi-
ratory flow were significantly greater in the Tioþ Tulo group than in the Tio group. In addition,
significant improvement in SGRQ score was observed in the Tioþ Tulo group only. The risk of447 2300.
ma-med.ac.jp (M. Ichinose).
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268 M. Ichinose et al.adverse events related to the study drugs was not increased.
Conclusion: In COPD patients, additional administration of transdermal tulobuterol to inhaled
tiotropium produced significant benefits in dyspnea and SGRQ score as well as pulmonary func-
tion. These benefits may be due to a reduction in pulmonary hyperinflation resulting from
improvement of peripheral airflow obstruction through tulobuterol via the systemic circula-
tion.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is an
inflammatory lung disease that occurs as a result of inha-
lation of harmful particles, such as those in cigarette
smoke. There is some concern that the number of COPD
patients will increase with the aging of the population. The
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) recommends the use of long-acting bronchodilators,
such as anticholinergics, b2-agonists, and methylxanthines,
for the management of stable COPD patients.1 In addition,
the combined use of bronchodilators with different mecha-
nisms of action results in greater potency and fewer
adverse effects, and is therefore recommended rather than
increasing the dose of a single agent when symptoms are
not well controlled by monotherapy.
Tiotropium, which has been available in Japan since
2004, is an anticholinergic that is inhaled once daily. Its
efficacy has been demonstrated in large-scale clinical
studies.2e10 In a recent study in which the use of all drugs
for COPD treatment except inhaled anticholinergics was
allowed, the efficacy and safety of tiotropium were
investigated in 5993 COPD patients over 4 years, in
comparison with a placebo. In this study, tiotropium was
demonstrated to improve pulmonary function and quality
of life (QOL), and to reduce the risk of exacerbations in
COPD and related hospitalizations.11 Based on such
evidence, inhaled tiotropium is regarded as a new thera-
peutic option for COPD in addition to b2-agonists and
methylxanthines.
Transdermal tulobuterol, which is frequently used for
COPD treatment, was developed in Japan as the world’s
first long-acting b2-agonist in a patch formulation. This
formulation of tulobuterol was designed to maintain drug
levels at constant effective concentrations over a 24-h
period when applied once daily.12,13 Administered this way,
tulobuterol exerts its effect through the systemic circula-
tion and provides a lower maximum blood concentration,
resulting in fewer systemic adverse effects, such as palpi-
tation and tremor, than oral formulations. In addition,
transdermal tulobuterol avoids the first-pass effect and is
expected to cause fewer adverse effects, such as gastro-
intestinal symptoms. To date, transdermal tulobuterol has
been launched in Japan, Korea, and China. The efficacy of
this drug in COPD patients was investigated in a randomized
comparative study using inhaled salmeterol, which is used
for the treatment of COPD.14 That study demonstrated
that, compared with inhaled salmeterol, transdermal
tulobuterol has an equivalent effect of improving pulmo-
nary function and is significantly superior in improving sleep
scores and QOL.14These findings suggest that the combined use of two long-
acting once-daily bronchodilators, transdermal tulobuterol
and inhaled tiotropium, with different mechanisms of
action, is an excellent treatment for COPD patients whose
symptoms are not well controlled by monotherapy.
However, there are few reports on the efficacy and safety of
combination therapy with these two drugs, and the benefits
of such a combination therapy have not been fully
confirmed. Therefore, we conducted a clinical study to
verify the efficacy and safety of the combined use of trans-
dermal tulobuterol and inhaled tiotropium in COPD patients.Methods
Subjects
The study was conducted in patients aged 40 years with
a clinical diagnosis of COPD who had the following condi-
tions: FEV1/FVC <70% 15e60 min after inhalation of
a short-acting b2-agonist, with FEV1 30e80% of the pre-
dicted value, in pulmonary function tests performed
during the screening period; current or past smoking
history; and relatively stable condition with persistent
dyspnea. All subjects were out-patients. Their status did
not change during the study period, and they remained
out-patients. Before the implementation of the study, the
study objectives were explained to patients and those who
provided informed consent to participate in the study
were enrolled.
The following patients were excluded: patients whose
major symptom was bronchial asthma; patients on
treatment with oral steroids; patients with respiratory
failure on home oxygen therapy; patients with previous
hypersensitivity to tulobuterol; patients with skin
diseases, such as atopic dermatitis, who are considered
unsuitable for treatment with transdermal tulobuterol;
patients with concurrent hyperthyroidism, hypertension,
heart disease, or diabetes mellitus, who are considered
unsuitable for treatment with b2-agonists; patients with
glaucoma; patients with dysuria associated with, for
example, benign prostatic hyperplasia; patients with
previous hypersensitivity to atropine and related
substances or to tiotropium; patients who were or may
have been pregnant, were breastfeeding, or intended to
become pregnant during the study period; and other
patients judged ineligible for the present clinical study by
the attending physician.
The study complied with the Declaration of Helsinki of
the World Medical Association. The protocol was approved
by the ethics committees of the institutions involved.
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The study was conducted as a multicenter parallel-group
comparison study. The assignment of subjects was per-
formed using a randomized subject assignment list
prepared based on a random number table by a central
registration center, a third party. After a 2-week run-in
period, patients were randomized to either a group
receiving inhaled tiotropium (one capsule of 18 mg) (the Tio
group) or a group receiving transdermal tulobuterol (2 mg)
in combination with inhaled tiotropium (one capsule of
18 mg) (the Tioþ Tulo group), and treated for 8 weeks
(Fig. 1). Tiotropium was inhaled using a designated inha-
lation device (HandiHaler), once daily between 7 a.m. and
9 a.m. Transdermal tulobuterol was applied to the chest,
back, or upper arm, once daily, after bathing and before
going to bed, by about 8 p.m.
Throughout the study period, the use of additional
bronchodilators was not allowed, but the use of short-
acting inhaled b2-agonists was allowed as necessary. A
2-week washout period was set for patients already on
treatment with a long-acting b2-agonist or tiotropium. For
patients who were on treatment with theophyllines,
inhaled steroids, antiallergic agents, antihistamines, anti-
tussives, expectorants, or anti-inflammatory enzyme
preparations from before the start of the study, the
concomitant use of these drugs was allowed. However, in
principle, the dose and dosing regimen were not to be
changed during the study period.
Pulmonary function tests and QOL assessment
The primary endpoints were pulmonary function and
severity of dyspnea. For pulmonary function, spirometry
was performed to determine FVC, FEV1, %FEV1, and IC at
the start and end of study treatment. Spirometry was
performed and measured between 9:00 am and noon. In
addition, the morning and evening peak expiratory flows
(PEFs) were measured using a peak flow meter (Mini-
Wright, ATS scale; Matsuyoshi) every day. Trough values of
peak flows were measured on getting up (before tiotropium
inhalation) and before going to bed (before tulobuterol
application). Severity of dyspnea was evaluated using the
Medical Research Council dyspnea scale at the start and
end of study treatment. As a secondary endpoint, QOL was
evaluated using the St. George’s Respiratory Questionnaire
(SGRQ), which is a disease-specific QOL questionnaire, at
the start and end of study treatment. In addition, forFigure 1 Studsafety, adverse events and abnormal laboratory values
were evaluated.
Statistical procedures
Data are expressed as means SD. For pulmonary function
indices, comparison of mean changes from baseline was
performed using the paired t-test, and between-group
comparisons of percentage changes from baseline were
performed using the Wilcoxon rank sum test. For PEFs,
comparisons of percentage changes from baseline were
performed using the Wilcoxon signed rank test, and
between-group comparisons of percentage changes from
baseline were performed using the Wilcoxon rank sum test.
For QOL scores, comparison of mean changes from baseline
were performed using the paired t-test, and between-group
comparisons of changes from baseline were performed
using Welch’s t-test. The significance level was set at less
than 5%.
Results
Subjects analyzed
One hundred and three patients were enrolled from 26
institutions in Japan. Of these, 50 and 53 patients were
randomly assigned to the Tio group and the Tioþ Tulo
group, respectively. During the study period, 11 patients
from the Tio group and nine patients from the Tioþ Tulo
group were withdrawn from the study. Reasons for with-
drawal of these patients were failure to meet the pulmo-
nary function test criteria (three of the Tio group and
three of the Tioþ Tulo group), no data available for the
screening period (one of the Tio group), treatment viola-
tion during the screening period (two of the Tio group and
two of the Tioþ Tulo group), treatment non-compliance
during the study period (one of the Tio group and one of
the Tioþ Tulo group), and treatment discontinuation
owing to, for example, adverse drug reactions (four of the
Tio group and three of the Tioþ Tulo group). As a result,
83 patients (39 patients from the Tio group and 44 patients
from the Tioþ Tulo group) were evaluated for efficacy
(Fig. 2).
The characteristics of the 83 subjects evaluated for
efficacy are shown in Table 1. No differences between the
treatment groups were noted in sex, age, height, weight, or
smoking status. In addition, although theophyllines,
expectorants, and short-acting b2-agonists were used asy protocol.
Figure 2 Allocation to treatment groups and status at follow-up.
270 M. Ichinose et al.concomitant drugs, no difference in the proportion of
subjects receiving concomitant drugs was noted between
the treatment groups. Regarding pulmonary function, FEV1
and %FEV1 tended to be higher in the Tio group. Regarding
QOL scores, the symptoms, impact, and total SGRQ scores
tended to be better in the Tio group.
Efficacy
Changes in pulmonary function indices assessed by
spirometry before and after treatment are shown in Table
2. After 8 weeks of treatment, mean FVC, FEV1, and %FEV1
values improved significantly from baseline in both groups
(P< 0.001 for each), whereas a significant improvement in
IC was observed in the Tioþ Tulo group only (P< 0.05).
In a between-group comparison of pulmonary function
indices, the percentage changes in FVC and FEV1 were not
significantly different between the two treatment groups.
For the percentage change in IC, a significant improvement
was observed in the Tioþ Tulo group compared with the Tio
group (P< 0.05; Fig. 3).
Time-course profiles of percentage changes in morning
and evening PEF values are shown in Fig. 4. The percentage
changes in both morning and evening PEF values signifi-
cantly increased from 1 week after the start of study
treatment (P< 0.001), and the improvement in PEF was
maintained throughout the treatment period. A between-
group comparison of percentage changes showed that the
increases in morning PEF (P< 0.05 at weeks 1, 2, 3, and 4)
and evening PEF (P< 0.05 at weeks 1, 3, 4, 6, and 8;
P< 0.01 at week 5) were significantly greater in the
Tioþ Tulo group than in the Tio group.
Severity of dyspnea was evaluated using the Medical
Research Council dyspnea scale at the start and end of
study treatment (P< 0.001 for each). Although dyspnea
decreased significantly in both treatment groups, the
differences were very similar (Table 2).
Regarding QOL, the mean baseline QOL score was higher
in the Tioþ Tulo group than the Tio group. The total SGRQscore decreased significantly from baseline in the Tioþ Tulo
group only (P< 0.001). The change was an improvement of
more than four points, which is defined as the minimal
clinically important difference value. An improvement of
four or more points was also observed in each component
(symptoms, activity, and impact) of the SGRQ, with signif-
icant differences in activity (P< 0.05) and impact
(P< 0.001). In a between-group comparison of changes,
improvements in the impact and total scores of the SGRQ
were significantly greater in the Tioþ Tulo group than in
the Tio group (P< 0.05 for each) (Fig. 5).
Safety
The following adverse events suspected to be related to
study treatment were observed in the Tio group: urticaria
(mild) in one subject, reduced masticatory force (mild) in
one subject, and dysuria (moderate) with increased blood
pressure (moderate) in one subject. Headache (mild) was
observed in one subject in the Tioþ Tulo group (Table 3).
Discussion
We conducted a study in which a b2-agonist, tulobuterol, in
a patch preparation, was given in combination with inhaled
tiotropium (an anticholinergic) to stable COPD patients for
8 weeks. As a result of this treatment, FVC and FEV1
improved significantly from baseline, but the changes were
not significantly different from those observed in the Tio
group. On the other hand, a significant improvement in IC
from baseline was observed in the Tioþ Tulo group, but not
in the Tio group. A between-group comparison of
percentage changes in IC revealed a significant improve-
ment in the Tioþ Tulo group. In addition, the percentage
changes in the morning and evening PEF values improved
significantly in the Tioþ Tulo group compared with the Tio
group. The change in total SGRQ score as a measure of QOL
was significantly greater in the Tioþ Tulo group than in the
Table 1 Patient characteristics (mean or mean SD).
Treatment group
Tio group Tuloþ Tio group
Patients (n) 39 44
Males (%) 94.9 97.7
Age (years) 69.9 5.5 70.2 7.4
Height (cm) 163.14 7.36 164.46 5.63
Weight (kg) 58.29 7.8 59.84 9.79
Severity by GOLD stage (%)
II 64.1 41.9
III 35.9 58.1
Current smokers (%) 23.1 31.8
Concomitant medication (%)
Theophyllines 25.6 36.4
Expectorants 17.9 20.5
Short-acting b2 agonists 10.3 15.9
Dyspnea (MRC scale) 2.5 0.8 2.6 0.9
Pulmonary function
testsa
FVC (L) 2.93 0.66 2.92 0.69
FEV1 (L) 1.39 0.41 1.20 0.35
FEV1% (%) 47.6 10.8 42.2 9.50
%FEV1 (%) 53.7 14.7 45.8 12.8
IC (L) 2.01 0.44 1.94 0.47
PEFa (L/min)
Morning 237.3 80.4 218.4 79.0
Evening 246.2 78.3 225.4 81.5
Quality of life
scoresa (units)
Symptoms 43.1 19.1 51.8 20.1
Activity 45.0 22.2 49.5 19.9
Impact 19.5 12.3 26.6 14.7
Total SGRQ 31.9 14.3 38.7 13.6
GOLD, Global Initiative for Chronic Obstructive Lung Disease;
MRC, Medical Research Council; PEF, peak expiratory flow;
SGRQ, St. George’s Respiratory Questionnaire.
a Before the run-in period (during treatment with
bronchodilators).
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of the SGRQ.
According to the GOLD, the international initiative
establishing guidelines for treatment of COPD, drug therapy
with bronchodilators is regarded as the mainstreamTable 2 Changes in pulmonary function, severity of dyspnea, a
Parameter Tio group
Baseline Week 8 Change
FVC (L) 2.94 0.11 3.16 0.11*** 0.22 0.05
FEV1 (L) 1.38 0.07 1.52 0.07*** 0.14 0.03
%FEV1 (%) 50.5 1.97 55.7 1.84*** 5.26 0.91
IC (L) 2.02 0.07 2.09 0.08 0.07 0.05
Dyspnea (MRC scale) 2.5 0.8 2.1 0.8*** 0.3 0.5
Total SGRQ (units) 31.6 2.36 29.6 2.52 1.96 1.16
MRC, Medical Research Council; SGRQ, St. George’s Respiratory Ques
*P< 0.05, ***P< 0.001 (within-group comparison: paired t-test).
Comparison between-groups: Wilcoxon rank sum test.treatment. Bronchodilators include long-acting agents such
as anticholinergics, b2-agonists and methylxanthines. These
agents have different mechanisms of action, and are used
according to the responsiveness and symptoms of individual
patients. When symptoms are not well controlled, the
combined use of bronchodilators with different mecha-
nisms of action is recommended in view of the main and
adverse effects, rather than increasing the dose of a single
agent.1 According to the reports of van Noord and
colleagues,10,15 combination therapy with inhaled tio-
tropium and inhaled formoterol improves pulmonary func-
tion better than monotherapy with each agent, and also
improves airflow obstruction, resting hyperinflation, and
the frequency of rescue therapy with short-acting
b2-agonists, compared with monotherapy with inhaled tio-
tropium. We selected anticholinergics because the revers-
ible airway contraction in COPD patients mainly depends on
acetylcholine released from the vagal nerve, and realized
the clinical usefulness of the combined use of an anticho-
linergic with a b2-agonist, which stimulates b2-receptors in
airway smooth muscle. The GOLD recommends the use of
an inhaled formulation of bronchodilators for COPD treat-
ment, from the standpoint of efficacy and safety. However,
because many COPD patients are elderly, their adherence
to inhalation therapy becomes an issue. Therefore, as an
option to enhance the treatment effect, a dosage form that
allows better patient adherence can be selected if
acceptable in terms of safety. Although long-acting anti-
cholinergics for COPD treatment are available only in
inhaled formulations, long-term b2-agonists are available in
patch formulations as well as in inhaled formulations.
Transdermal tulobuterol is a b2-agonist designed to
maintain drug levels at constant effective concentrations
over a 24-h period when applied once daily. In addition, it
has an improved safety profile, with a lower maximum
blood drug concentration.12,13 Tamura and coworkers
reported that treatment adherence is better with the patch
formulation than with the inhaled formulation.16 Among
long-acting b2-agonists, inhaled salmeterol in a twice-daily
regimen is globally used.17,18 Recently, we conducted
a randomized parallel-group comparison study using
inhaled salmeterol and transdermal tulobuterol. The study
showed that transdermal tulobuterol, compared with
inhaled salmeterol, has an equivalent effect in improving
pulmonary function, such as FEV1, FVC, and morning and
evening PEF values, and is significantly superior innd quality of life scores (mean SD).
Tioþ Tulo group Comparison
between-groupsBaseline Week 8 Change
2.91 0.11 3.18 0.10*** 0.28 0.05 PZ 0.5379
1.24 0.06 1.37 0.07*** 0.13 0.03 PZ 0.6813
44.3 1.70 49.1 1.89*** 4.80 0.93 PZ 0.6948
1.96 0.08 2.10 0.07* 0.14 0.06 PZ 0.2837
2.6 0.9 2.1 0.8*** 0.5 0.6 PZ 0.3798
38.4 2.04 32.0 2.22*** 6.48 1.72 PZ 0.0325
tionnaire.
Figure 3 Effect of tulobuterol used in combination therapy
on percentage change in IC. The percentage change from
baseline at week 8 was assessed in each group. Between-group
comparisons were performed for percentage changes.
)P< 0.05 (Tio group versus Tioþ Tulo group); between-group
comparison using the Wilcoxon rank sum test DIF, difference.
272 M. Ichinose et al.improving sleep scores. In addition, only transdermal tulo-
buterol resulted in a significant improvement in QOL (total
SGRQ score) from baseline.14 These findings confirmed that
transdermal tulobuterol can replace inhaled salmeterol.
Therefore, the use of transdermal tulobuterol, selected as
a long-acting b2-agonist, in combination with inhaled tio-
tropium for long-term management of COPD, is considered
a promising treatment option.
In the present study, in which transdermal tulobuterol
was used in combination with inhaled tiotropium, only the
Tioþ Tulo group showed a significant improvement in IC
from baseline, with a significant between-group difference
in percentage change in IC. This may be because extensive
bronchodilation involving peripheral airways was induced
by the combined use of transdermal tulobuterol with
inhaled tiotropium, and because the drug was delivered to
a wider extent of the airway through the blood circula-
tion.19,20 In fact, the morning and evening PEF values were
significantly increased in both groups, and the percentageFigure 4 Effect of tulobuterol used in combination therapy on (A
group comparisons were performed for percentage changes. Within
baseline) for all measurements. Between-group comparison: Wilc
Tioþ Tulo group).change in either morning PEF or evening PEF tended to
show more significant improvement in the Tioþ Tulo group
than in the Tio alone group. These findings suggest that the
combined use of transdermal tulobuterol with inhaled tio-
tropium improves obstruction of the central and peripheral
bronchi more than monotherapy with inhaled tiotropium.
FEV1 and PEF are both central airway parameters; theo-
retically, the FEV1 should change in the same manner as the
PEF. No significant difference in FEV1 was observed, and
only the PEF showed a significant difference, probably
because the FEV1 change was small while, conversely, the
change in PEF was large.
We propose the following possible explanations for the
additive effects of transdermal tulobuterol and tiotropium.
First, the effects of b2-agonists and anticholinergic agents
may be additive because b2 receptors and muscarinic
receptors (M3) have different mechanisms of action. A
recent report10 described additive effects of b2-agonists
and anticholinergic agents. Second, b2 receptors and
muscarinic receptors (M3) are both distributed in central
and distal airways.21 Theoretically both agents affect all
airways. However, vagal nerve fibers mainly innervate
central airways.22 Therefore stimulated muscarinic recep-
tors (M3) may be mainly found in central airways. Anti-
cholinergic agents may improve function in central airways
rather than peripheral airways because they block cholin-
ergic impulses derived from vagal nerve fibers. Of course, it
is also possible that peripheral muscarinic receptors (M3)
are stimulated by acetylcholine of non-neuronal origin.
Regarding the treatment of COPD, it has been reported
that improvements not only in pulmonary function but also
in QOL are important.23e26 The results of the present study,
in which transdermal tulobuterol was used in combination
with inhaled tiotropium, showed significant improvements
in the total SGRQ score as well as its activity and impact
scores in the Tioþ Tulo group compared with the Tio group.
The SGRQ is a disease-specific health-related QOL index in
COPD patients. The SGRQ consists of ‘symptoms’, assessing
distress owing to respiratory symptoms; ‘activity’, assessing
the effects of disturbance of mobility and physical activity
caused by dyspnea; and ‘impact’, assessing the psychologic
and social impact of the disease on daily life and
well-being.27,28 Of the three components, the impact score
is highly important as a measurement of health-related) morning and (B) evening peak expiratory flow (PEF). Between-
-group comparison: Wilcoxon signed rank test, P< 0.001 (versus
oxon rank sum test; )P< 0.05, ))P< 0.01 (Tio group versus
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Figure 5 Effect of tulobuterol used in combination therapy on quality of life (St. George’s Respiratory Questionnaire, SGRQ,
scores). Between-group comparisons were performed to assess changes. Within-group comparison: paired t-test; )P< 0.05,
)))P< 0.001 (versus baseline). Between-group comparison: Welch’s t-test, yP< 0.05 (Tio group versus Tioþ Tulo group).
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induced by the combined use of transdermal tulobuterol is
significant. The reason for the improvement of QOL by the
combined use of transdermal tulobuterol may be that
tulobuterol improved peripheral airway obstruction exten-
sively via the systemic circulation, resulting in a reduction
in pulmonary hyperinflation.29,30 Regarding this point, de
Torres and associates have reported that the effect of
improving IC correlates with a change indicating an
improvement in QOL.31
Regarding safety, adverse effects were observed in
three subjects in the Tio group and one subject in the
Tioþ Tulo group, but none of these effects were serious.
This result suggests that the combined use of transdermal
tulobuterol with inhaled tiotropium does not increase the
risk of adverse effects.
There are some limitations of the present study. First,
because this study was an open-label study, it is possible
that biases on the part of patients and/or investigators
influenced patient-reported outcomes and other factors in
the SGRQ. Second, the imbalance in the baseline QOL
scores might have contributed to the difference in the
change from baseline between the two groups, because the
Tioþ Tulo group had more room for improvement. Third,
the cardiovascular effects of the two bronchodilators were
not objectively assessed. It seems that tulobuterol affected
the small airways following systemic delivery. This effect
will have to be evaluated in a future study. However, theTable 3 Safety (frequency of adverse events).
No. Symptom Tio Tioþ Tulo
1 Palpitation 0 0
2 Increased blood
pressure (self-monitoring)
1 0
3 Finger tremor 0 0
4 Sputum 1 0
5 Urticaria 1 0
6 Reduced masticatory force 1 0
7 Dysuria 1 0
8 Pollakiuria 0 0
9 Headache 0 1present findings demonstrate the additive effects of
transdermal tulobuterol to inhaled tiotropium. The
observed additive effect of transdermal tulobuterol is
suggested to be due to a reduction in pulmonary hyperin-
flation resulting from the drug’s effect in improving
peripheral airflow obstruction via the systemic circulation.
In COPD patients, many of whom are elderly, the combined
use of inhaled tiotropium and transdermal tulobuterol is
considered to be an ideal combination therapy for COPD.
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